000162449 001__ 162449
000162449 005__ 20251017144644.0
000162449 0247_ $$2doi$$a10.1021/acsami.5c10402
000162449 0248_ $$2sideral$$a145020
000162449 037__ $$aART-2025-145020
000162449 041__ $$aeng
000162449 100__ $$aPérez, Estela
000162449 245__ $$aBiomimetic apatite nanoparticles and microcrystalline tyrosine as biocompatible vaccine adjuvants: performance in a bluetongue virus sheep model
000162449 260__ $$c2025
000162449 5060_ $$aAccess copy available to the general public$$fUnrestricted
000162449 5203_ $$aAluminum oxyhydroxide (AlOOH) is the most widely used vaccine adjuvant, but its known adverse effects prompt the finding of other, safer alternative adjuvants. This study compares in sheep the global performance and safety of vaccine prototypes against bluetongue virus (BTV) formulated with AlOOH, biomimetic apatite nanoparticles (ApNPs), and microcrystalline tyrosine (MCT). Five groups of 6 sheep were included in the study: control, BTV serotype 4 alone, and BTV-4 combined either with AlOOH, ApNPs, or MCT. Adjuvants were fully characterized. Group specific antibodies against BTV-4 were observed in all treatment groups, including BTV-4 alone. After booster inoculation, ApNPs or MCT groups responded immediately, and it was delayed for BTV-4 and AlOOH groups. Comparable neutralizing antibody responses were observed in all treatment groups but were earlier for BTV-4, ApNPs, and MCT groups when compared with the AlOOH group. No significant systemic alterations were observed during the study. The AlOOH group developed more pronounced local reactions that persisted throughout the 133-day study and were evident as post-mortem granulomas. ApNPs and MCT are biocompatible, safer, and viable alternative adjuvants for sheep vaccines. BTV alone might also be suitable for this purpose. This work is the first demonstrating the suitability of biocompatible alternative adjuvants in sheep vaccines.
000162449 536__ $$9info:eu-repo/grantAgreement/ES/MICINN/CEX2023-001286-S$$9info:eu-repo/grantAgreement/ES/MICINN/PID2021-127847OB-I00$$9info:eu-repo/grantAgreement/ES/MICINN/RTI2018-096172-B-C33
000162449 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000162449 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000162449 700__ $$0(orcid)0000-0002-6873-5244$$aSebastián, Víctor$$uUniversidad de Zaragoza
000162449 700__ $$0(orcid)0000-0002-2685-1730$$aRodríguez-Largo, Ana
000162449 700__ $$ade Miguel, Ricardo
000162449 700__ $$0(orcid)0000-0002-9723-9004$$aGómez, Álex$$uUniversidad de Zaragoza
000162449 700__ $$aKramer, Matthias F.
000162449 700__ $$aGraessel, Anke
000162449 700__ $$aParra-Torrejón, Belén
000162449 700__ $$aDelgado-López, José Manuel
000162449 700__ $$aUtrilla-Trigo, Sergio
000162449 700__ $$aJiménez-Cabello, Luis
000162449 700__ $$aOrtego, Javier
000162449 700__ $$0(orcid)0000-0002-1204-4356$$ade Blas, Ignacio$$uUniversidad de Zaragoza
000162449 700__ $$aReina, Ramsés
000162449 700__ $$aPérez, Marta
000162449 700__ $$0(orcid)0000-0002-2053-9842$$aLuján, Lluís$$uUniversidad de Zaragoza
000162449 7102_ $$11009$$2773$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Sanidad Animal
000162449 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química
000162449 773__ $$g17, 32 (2025), 45538-45554$$pACS appl. mater. interfaces$$tACS applied materials & interfaces$$x1944-8244
000162449 8564_ $$s15491428$$uhttps://zaguan.unizar.es/record/162449/files/texto_completo.pdf$$yVersión publicada
000162449 8564_ $$s3168554$$uhttps://zaguan.unizar.es/record/162449/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000162449 909CO $$ooai:zaguan.unizar.es:162449$$particulos$$pdriver
000162449 951__ $$a2025-10-17-14:33:25
000162449 980__ $$aARTICLE